Pricing Log in Create free account

BridgeBio Pharma, Inc. (BBIO) vs Kymera Therapeutics, Inc. (KYMR)

BridgeBio Pharma, Inc. and Kymera Therapeutics, Inc. are both Biotechnology companies. BridgeBio Pharma, Inc. is the larger, with a market value of $14.5B against $10.9B — 1.3× the size. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 167.3% against 134.8%. Kymera Therapeutics, Inc. has the higher net margin (0.00% vs −62.6%) and the lower return on invested capital (−39.3% vs 0.00%). Across the 17 metrics below, Kymera Therapeutics, Inc. leads on 9 and BridgeBio Pharma, Inc. on 8.

Valuation

Metric BBIO KYMR Biotechnology median
P/E n/m n/m 10.26
P/S 15.49 119.82 9.18
P/B n/m 7.79 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 15.90 110.58 8.98
Earnings yield (4.07%) (2.88%) (34.89%)
Free cash flow yield (2.58%) (2.30%) (24.52%)

Profitability

Metric BBIO KYMR Biotechnology median
Gross margin 94.34% 100.00% 65.16%
Operating margin (38.52%) 0.00% 0.00%
Net margin (62.62%) 0.00% 0.00%
Free cash flow margin (39.11%) 0.00% 0.00%
Return on equity 26.22% (27.29%) (50.12%)
Return on assets (37.48%) (24.36%) (45.60%)
Return on invested capital 0.00% (39.30%) 0.00%

Growth

Metric BBIO KYMR Biotechnology median
Revenue growth (TTM) 167.27% 134.84% 6.26%
EPS growth (last fiscal year) (31.25%) (23.83%) 29.88%
Revenue growth, 5-year CAGR 127.44% 2.87% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BBIO KYMR Biotechnology median
Debt to equity (1.17) 0.00 0.00
Current ratio 2.09 11.13 4.89
Net debt to EBITDA (2.47) 2.42 1.01

Dividend

Metric BBIO KYMR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BBIO KYMR Biotechnology median
Market cap 14.47b 10.94b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack